Scrip's Five Must-Know Things - Mar.9, 2026

What It Covers

Five pharma business developments for the week ending March 6, 2026: MFN pricing stalls European launches, FDA vaccine leadership criticism, AI investment pressure on CRDMOs, neuroscience funding revival signals, and UCB's $1.1B China biotech deal.

Key Questions Answered

• •MFN Pricing Risk: Smaller biotech firms like Insmed are halting European launches and pausing ex-US outlicensing deals until MFN policy clarity emerges. If Medicare Part D parity is enforced broadly, executives warn it could financially devastate most biotech and pharma companies operating globally.
• •FDA Leadership Divide: Pfizer CEO Albert Bourla publicly separates FDA's career scientists — whom he calls productive collaborators — from CBER director Vinay Prasad, who overruled staff recommendations on Moderna's flu vaccine filing. Bourla frames current vaccine policy disruption as a temporary anomaly that will self-correct.
• •CRDMO AI Strategy: CRDMOs must invest in AI to retain pharma partnerships, but Lonza's SVP Matthew Moorcroft advises running AI adoption in parallel with data cleanup rather than sequentially. Aragon avoids customer IP risk by training models exclusively on non-proprietary external databases, including failure data.
• •Neuroscience Funding Shift: J&J Innovation is deploying a portfolio approach — funding seven to eight preclinical Alzheimer's and Parkinson's companies simultaneously with minimal deep diligence — to navigate high failure rates. ADDF predicts 2026 becomes the year of brain health as corporate VC risk appetite increases.